Baolingbao Biology Co Ltd (002286) - Net Assets
Based on the latest financial reports, Baolingbao Biology Co Ltd (002286) has net assets worth CN¥2.30 Billion CNY (≈ $336.96 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.93 Billion ≈ $428.50 Million USD) and total liabilities (CN¥625.57 Million ≈ $91.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002286 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.30 Billion |
| % of Total Assets | 78.64% |
| Annual Growth Rate | 17.03% |
| 5-Year Change | 23.18% |
| 10-Year Change | 48.1% |
| Growth Volatility | 42.69 |
Baolingbao Biology Co Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Baolingbao Biology Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Baolingbao Biology Co Ltd.
Annual Net Assets for Baolingbao Biology Co Ltd (2006–2025)
The table below shows the annual net assets of Baolingbao Biology Co Ltd from 2006 to 2025. Also explore 002286 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.23 Billion ≈ $326.85 Million |
+9.41% |
| 2024-12-31 | CN¥2.04 Billion ≈ $298.74 Million |
+2.93% |
| 2023-12-31 | CN¥1.98 Billion ≈ $290.25 Million |
-1.04% |
| 2022-12-31 | CN¥2.00 Billion ≈ $293.30 Million |
+10.54% |
| 2021-12-31 | CN¥1.81 Billion ≈ $265.33 Million |
+13.37% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.04 Million |
+2.07% |
| 2019-12-31 | CN¥1.57 Billion ≈ $229.30 Million |
+1.62% |
| 2018-12-31 | CN¥1.54 Billion ≈ $225.64 Million |
+1.11% |
| 2017-12-31 | CN¥1.53 Billion ≈ $223.17 Million |
+1.13% |
| 2016-12-31 | CN¥1.51 Billion ≈ $220.69 Million |
+2.03% |
| 2015-12-31 | CN¥1.48 Billion ≈ $216.29 Million |
+1.98% |
| 2014-12-31 | CN¥1.45 Billion ≈ $212.09 Million |
+0.98% |
| 2013-12-31 | CN¥1.44 Billion ≈ $210.03 Million |
+75.59% |
| 2012-12-31 | CN¥817.45 Million ≈ $119.62 Million |
+7.48% |
| 2011-12-31 | CN¥760.53 Million ≈ $111.29 Million |
+8.17% |
| 2010-12-31 | CN¥703.11 Million ≈ $102.89 Million |
+6.11% |
| 2009-12-31 | CN¥662.61 Million ≈ $96.96 Million |
+178.35% |
| 2008-12-31 | CN¥238.05 Million ≈ $34.83 Million |
+23.17% |
| 2007-12-31 | CN¥193.28 Million ≈ $28.28 Million |
+71.76% |
| 2006-12-31 | CN¥112.53 Million ≈ $16.47 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Baolingbao Biology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1101.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥816.72 Million | 36.57% |
| Other Components | CN¥1.42 Billion | 63.43% |
| Total Equity | CN¥2.23 Billion | 100.00% |
Baolingbao Biology Co Ltd Competitors by Market Cap
The table below lists competitors of Baolingbao Biology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
29METALS Ltd
AU:29M
|
$470.55 Million |
|
Logan Energy Corp
V:LGN
|
$470.58 Million |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
$470.76 Million |
|
mF International Limited Ordinary Shares
NASDAQ:MFI
|
$470.84 Million |
|
LAY-OUT Planning Consultants Co. Ltd.
SHE:300989
|
$470.15 Million |
|
Hefei Taihe Optoelectronic
SHG:603656
|
$470.09 Million |
|
YungShin Global Holding Corp
TW:3705
|
$469.95 Million |
|
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
|
$469.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Baolingbao Biology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,041,529,687 to 2,233,596,072, a change of 192,066,386 (9.4%).
- Net income of 150,626,576 contributed positively to equity growth.
- Dividend payments of 31,933,148 reduced retained earnings.
- Other factors increased equity by 73,372,957.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥150.63 Million | +6.74% |
| Dividends Paid | CN¥31.93 Million | -1.43% |
| Other Changes | CN¥73.37 Million | +3.28% |
| Total Change | CN¥- | 9.41% |
Book Value vs Market Value Analysis
This analysis compares Baolingbao Biology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.44x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.02x to 1.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.65 | CN¥8.46 | x |
| 2007-12-31 | CN¥1.12 | CN¥8.46 | x |
| 2008-12-31 | CN¥1.18 | CN¥8.46 | x |
| 2009-12-31 | CN¥3.83 | CN¥8.46 | x |
| 2010-12-31 | CN¥2.59 | CN¥8.46 | x |
| 2011-12-31 | CN¥2.80 | CN¥8.46 | x |
| 2012-12-31 | CN¥3.02 | CN¥8.46 | x |
| 2013-12-31 | CN¥4.19 | CN¥8.46 | x |
| 2014-12-31 | CN¥3.82 | CN¥8.46 | x |
| 2015-12-31 | CN¥3.97 | CN¥8.46 | x |
| 2016-12-31 | CN¥3.97 | CN¥8.46 | x |
| 2017-12-31 | CN¥3.99 | CN¥8.46 | x |
| 2018-12-31 | CN¥4.30 | CN¥8.46 | x |
| 2019-12-31 | CN¥4.45 | CN¥8.46 | x |
| 2020-12-31 | CN¥4.49 | CN¥8.46 | x |
| 2021-12-31 | CN¥4.86 | CN¥8.46 | x |
| 2022-12-31 | CN¥5.42 | CN¥8.46 | x |
| 2023-12-31 | CN¥5.51 | CN¥8.46 | x |
| 2024-12-31 | CN¥5.51 | CN¥8.46 | x |
| 2025-12-31 | CN¥5.87 | CN¥8.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Baolingbao Biology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.74%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.48%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 1.25x
- Recent ROE (6.74%) is below the historical average (6.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 17.78% | 7.77% | 0.51x | 4.51x | CN¥8.75 Million |
| 2007 | 17.23% | 8.04% | 0.69x | 3.11x | CN¥13.97 Million |
| 2008 | 18.81% | 8.35% | 0.72x | 3.12x | CN¥20.97 Million |
| 2009 | 5.93% | 7.48% | 0.48x | 1.64x | CN¥-26.99 Million |
| 2010 | 6.09% | 5.94% | 0.70x | 1.47x | CN¥-27.51 Million |
| 2011 | 7.33% | 5.86% | 0.85x | 1.46x | CN¥-20.29 Million |
| 2012 | 8.41% | 7.02% | 0.88x | 1.36x | CN¥-13.02 Million |
| 2013 | 2.86% | 4.56% | 0.54x | 1.17x | CN¥-102.43 Million |
| 2014 | 1.57% | 2.50% | 0.52x | 1.22x | CN¥-122.16 Million |
| 2015 | 2.77% | 3.42% | 0.63x | 1.29x | CN¥-106.87 Million |
| 2016 | 3.28% | 3.58% | 0.71x | 1.28x | CN¥-101.19 Million |
| 2017 | 3.26% | 3.12% | 0.76x | 1.38x | CN¥-102.66 Million |
| 2018 | 2.79% | 2.48% | 0.67x | 1.67x | CN¥-111.05 Million |
| 2019 | 2.25% | 1.95% | 0.72x | 1.61x | CN¥-121.47 Million |
| 2020 | 3.12% | 2.43% | 0.79x | 1.64x | CN¥-110.07 Million |
| 2021 | 11.12% | 7.29% | 0.91x | 1.67x | CN¥20.26 Million |
| 2022 | 6.64% | 4.91% | 0.90x | 1.50x | CN¥-67.27 Million |
| 2023 | 2.72% | 2.14% | 0.95x | 1.34x | CN¥-144.38 Million |
| 2024 | 5.44% | 4.63% | 0.90x | 1.31x | CN¥-92.99 Million |
| 2025 | 6.74% | 5.48% | 0.99x | 1.25x | CN¥-72.73 Million |
Industry Comparison
This section compares Baolingbao Biology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,098,994,056
- Average return on equity (ROE) among peers: 5.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Baolingbao Biology Co Ltd (002286) | CN¥2.30 Billion | 17.78% | 0.27x | $470.40 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $128.42 Million | 3.01% | 0.85x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.38 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $423.50 Million | 7.52% | 0.41x | $663.06 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $208.96 Million | -6.84% | 0.25x | $552.91 Million |
| Chengzhi Shareholding Co Ltd (000990) | $975.70 Million | 5.10% | 0.96x | $1.58 Billion |
| Hualan Biological EngineeringInc (002007) | $588.30 Million | 13.43% | 0.39x | $3.51 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.64 Billion | 3.27% | 0.76x | $1.16 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $754.76 Million | 13.88% | 0.10x | $4.84 Billion |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $4.11 Billion | 14.16% | 0.65x | $1.62 Billion |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more